Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
The response includes several label-consistent mechanistic and liver-monitoring statements (e.g., transaminase elevations, dose-related incidence, pregnancy and breastfeeding contraindication-like cautions), but it also contains at least one clear numeric contradiction and multiple safety-related symptom/severity claims that are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) works by inhibiting HMG-CoA reductase/cholesterol synthesis in the liver.
Supported by 12.1 Mechanism of Action (inhibition of HMG-CoA reductase and cholesterol synthesis in the liver).
Lipitor helps to lower LDL (bad) cholesterol levels in the blood.
Supported by 12.1 (reduces LDL-C).
Lipitor can cause liver enzyme (transaminase) elevations.
Supported by 5.2 (persistent elevations in serum transaminases; incidence and dose-related rates).
The risk of liver enzyme abnormalities is higher at higher doses of Lipitor (including 80 mg).
Supported by 5.2 (incidence increases with 10/20/40/80 mg; 2.3% at 80 mg).
Lipitor should be used with caution in patients with a history of liver disease; active liver disease is a contraindication.
Supported by 5.2 (caution; active liver disease or unexplained persistent transaminase elevations are contraindications) and 4.1 (active liver disease).
Lipitor is not recommended during pregnancy / may cause fetal harm when administered to a pregnant woman; discontinue if pregnancy occurs.
Supported by 4.3 Pregnancy.
Lipitor is not recommended during breastfeeding; women who require Lipitor treatment should not breastfeed their infants.
Supported by 4.4 Nursing mothers.
It is recommended to perform liver function tests prior to and at 12 weeks after initiation and after dose increases, and periodically thereafter.
Supported by 5.2 and 17.2 (liver enzymes monitoring guidance).
Upon persistent transaminase elevations, dose reduction, drug interruption, or discontinuation is recommended; transaminases return toward pretreatment levels after dose reduction/interrupt/discontinuation.
Supported by 5.2 (recommendations and normalization without sequelae).
Unsupported Statements
Lipitor is used to reduce the risk of heart disease.
Not supported by provided label excerpt under Indications (1) or other provided sections.
Lipitor can cause liver failure.
No liver failure statement appears in provided label excerpts (only biochemical liver function abnormalities and jaundice in one patient are mentioned).
The risk of liver damage with Lipitor is relatively low.
Label provides incidence values but does not use or support the qualitative phrasing 'relatively low' based on the provided excerpts.
The risk of liver enzyme elevations with Lipitor is approximately 1.5% to 2.5%.
Dose-specific incidence values in the provided label excerpts include 0.2% (10 mg), 0.2% (20 mg), 0.6% (40 mg), and 2.3% (80 mg) with an overall 0.7%; the 1.5% to 2.5% range is not consistently supported.
The symptoms of liver damage with Lipitor can be subtle.
No symptom-subtlety statement appears in provided label excerpts.
The symptoms of liver damage with Lipitor may not appear until the damage is severe.
No such delayed/severity-based symptom statement appears in provided label excerpts.
Common symptoms of liver damage with Lipitor include fatigue.
Fatigue is not listed as a liver-damage symptom in the provided excerpts.
Common symptoms of liver damage with Lipitor include loss of appetite.
Loss of appetite is not listed as a liver-damage symptom in the provided excerpts.
Common symptoms of liver damage with Lipitor include nausea and vomiting.
Nausea appears as an adverse reaction, but the label excerpt does not link nausea/vomiting specifically as common symptoms of liver damage.
Common symptoms of liver damage with Lipitor include abdominal pain.
Abdominal pain is not listed as a symptom of liver damage in the provided excerpts (only other general adverse terms appear).
Common symptoms of liver damage with Lipitor include jaundice.
The label states one patient developed jaundice and that other LFT increases were not associated with jaundice/clinical signs; it does not support jaundice as a 'common symptom.'
The risk of liver damage with Lipitor is higher in people taking other medications that can damage the liver.
No statement in provided excerpts supports increased liver damage risk with 'other medications that can damage the liver.' (Drug interaction section excerpt provided addresses myopathy risk, not liver toxicity broadly.)
Taking the lowest effective dose of Lipitor can reduce the risk of liver damage.
Label supports dose reduction/withdrawal based on persistent ALT/AST elevations, but the provided excerpts do not explicitly state 'lowest effective dose' as a risk-reduction principle for liver damage.
Avoiding other medications that can damage the liver can reduce the risk of liver damage with Lipitor.
No such statement appears in provided excerpts.
Informing a doctor of pre-existing liver problems or liver disease can reduce the risk of liver damage with Lipitor.
Label provides caution/contraindication and monitoring recommendations but does not explicitly state that informing the doctor reduces risk.
Zocor (simvastatin), Crestor (rosuvastatin), Vytorin (ezetimibe and simvastatin), Pravachol (pravastatin) are alternatives to Lipitor.
No provided label excerpts list alternative statins or specific branded alternatives as selection guidance.
The most common side effect of Lipitor is muscle pain or weakness.
Label excerpt lists myalgia and muscle-related adverse reactions, but does not establish 'most common' or 'muscle pain or weakness' as the single most common side effect in the provided material.
If a person has liver problems, they should consult with a doctor before taking Lipitor.
Provided excerpts contain cautions/contraindications and monitoring recommendations but do not include an explicit patient counseling directive to 'consult with a doctor before taking'.
If a person has liver problems, a doctor may recommend a lower dose of Lipitor.
Label supports dose reduction/withdrawal based on persistent ALT/AST elevations, but does not explicitly frame it as 'lower dose' for 'liver problems' broadly.
Lipitor can start working within a few days to a few weeks of starting treatment.
No onset timing statement appears in the provided excerpts.
If a person experiences liver damage while taking Lipitor, they should consult with a doctor.
Label provides dose reduction/interrupt/discontinuation and monitoring guidance, but the provided excerpts do not contain an explicit 'consult with a doctor' directive tied to liver damage.
If a person experiences liver damage while taking Lipitor, a doctor may recommend alternative treatments.
No alternative-treatment recommendation is present in provided excerpts.
Contradictions
High
AI Statement
In people who take high doses of Lipitor (80 mg or higher), the risk of liver enzyme elevations increases to 5.5% to 7.5%.
Label Reference
5.2 Liver Dysfunction (incidence of persistent transaminase elevations: 2.3% at 80 mg; no 5.5%–7.5% range provided).
Important Omissions
Boxed warning presence/contents and specific boxed-warning compliance cannot be evaluated from the provided excerpts; potential omission of boxed warning claims in the AI response.
Importance:
Moderate
Drug interaction warnings relevant to atorvastatin (e.g., strong CYP3A4 inhibitors, cyclosporine, etc.) are not addressed in the AI response.
Importance:
Moderate
Contraindication details beyond active liver disease (e.g., pregnancy/nursing) are not fully covered in the AI response (though pregnancy and nursing are addressed).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
A clear numeric contradiction (5.5%–7.5% vs label 2.3% at 80 mg) and multiple unsupported symptom/severity assertions could mislead risk perception and clinical interpretation. Some safety-related monitoring and contraindication-like guidance (pregnancy, breastfeeding, liver testing/thresholds) aligns with the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
At least one label-contradictory liver enzyme incidence range and several unsupported symptom/severity and counseling/alternative-specific claims.
Suggested Improvement
Remove or correct the contradicted numeric range; avoid asserting symptom profiles/severity progression or 'common' symptom lists not supported by provided label excerpts; restrict liver-related statements to label-supported findings (transaminase elevations, jaundice occurrence, monitoring schedule, and ALT/AST threshold actions). Add label-supported dosing/interaction guidance if making safety claims.